GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cambium Bio CMB.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.36

-10.00%

Close of 4 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

A$641,638

FY2017FY2026

Net income

−A$4.1m

FY2017FY2026

Free cash flow

−A$2.8m

FY2017FY2026

Shareholders' equity

A$2.4m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueA$641,638A$670,056A$719——A$7.1mA$1.7mA$25,077A$575,406A$10.0m
Research and developmentA$3.0mA$2.6mA$210,708A$473,415A$1.8mA$1.4mA$1.2mA$2.4mA$4.0mA$4.5m
Operating income−A$4.1m−A$4.3m−A$2.0m−A$2.4m−A$4.8mA$2.3m−A$3.3m−A$7.1m−A$7.3mA$975,583
Net income−A$4.1m−A$3.8m−A$2.3m−A$3.4m−A$4.3mA$2.8m−A$894,046−A$6.0m−A$5.2mA$3.3m
Diluted earnings per share-0.16-0.18-0.19-1.10-1.410.01-0.00-2.37-2.431.53

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsA$3.8mA$3.3mA$5.6mA$2.5mA$2.6mA$8.5mA$4.8mA$2.5mA$5.0mA$9.2m
Cash and short-term investmentsA$1.1mA$166,405A$2.9mA$302,792A$164,395A$3.8mA$981,845A$255,463A$1.1mA$4.1m
Total liabilitiesA$1.4mA$1.5mA$2.9mA$2.6mA$1.5mA$4.4mA$3.7mA$8.9mA$2.1mA$1.1m
DebtA$164,894A$482,708A$468,320A$1.9mA$1.0mA$13,846A$1.1mA$3.8mA$1.0mA$392,892
Shareholders' equityA$2.4mA$1.8mA$2.8m−A$1.8mA$1.1mA$4.1mA$1.1m−A$6.4mA$2.9mA$8.1m
Shares outstanding25m21m12m3m3m305m292m3m2m2m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−A$2.8m−A$5.2m−A$155,864−A$660,464−A$3.6mA$2.4m−A$1.9m−A$3.6m−A$4.2mA$3.6m
Capital spending−A$2,638−A$5,255−A$4−A$4−A$8,466−A$7,784−A$7,784−A$7,624−A$150,970−A$149,950
Free cash flow−A$2.8m−A$5.2m−A$155,868−A$660,468−A$3.6mA$2.4m−A$2.0m−A$3.6m−A$4.4mA$3.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue—-38.1%-9.5%
Operating income19.7%—-4.5%
Net income6.6%—1.4%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-638.7%———
Net margin-605.4%———

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-2.2-2.6-2.1-0.3-1.1284.5-1312.7-1.2-2.32.6
Price to sales14.315.1———111.1—283.421.00.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 4 Jul 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.